Dr. Mohamed H. El Dinali, MD

Dr. El Dinali practices at Pikeville Medical Center in Pikeville, Kentucky, part of Pikeville Hospital.

Dr. El Dinali's NPI, 1134499858, was assigned on January 11, 2012. Dr. El Dinali holds Kentucky license 50817.

Dr. El Dinali's primary practice is Pikeville Medical Center, at 911 Bypass Road, Pikeville, KY 41501 in Pike County. The practice phone is (606) 437-3500.

Dr. El Dinali's primary practice is Pikeville Medical Center in Pikeville, Kentucky, part of Pikeville Hospital. The medical group on file is Pikeville Medical Center. Dmand AI also links Dr. El Dinali to 1 more hospital, named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. El Dinali practices, 2 sites in all. Vendor and product names are available with a free account.

Hematology and oncology is Dr. El Dinali's primary specialty in the NPI Registry, under taxonomy code 207RH0003X. Dmand AI has Dr. El Dinali's licenses on file in 2 states: Kentucky and Illinois.

CMS data shows 422 Medicare services from Dr. El Dinali across 4 procedure codes in 2024, all of them office visits, for 128 Medicare patients. Medicare paid $18,088 for them. Every service was in a facility, such as a hospital, rather than an office.

CMS counts 128 Medicare patients who saw Dr. El Dinali in 2024. The largest group is 65 to 74, with 56 patients. 75% of them have high blood pressure, and 75% have high cholesterol. 29% are also on Medicaid. Their average risk score is 2.10, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. El Dinali's median patient age at 66, with 56% women.

In 2024, Dr. El Dinali wrote 639 Medicare Part D claims for 117 patients. 69% of them were for generic drugs. CMS names the drug for 473 of them, across 21 drugs with 11 or more claims each, at $1,927,844 in total drug cost. In 2023, CMS named 262 claims across 12 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 93 out of 100 for Dr. El Dinali for performance year 2024, reported as part of a group. Dr. El Dinali accepts Medicare assignment, so Medicare's approved amount is taken as full payment.

Dmand AI links 6 papers to Dr. El Dinali, published from 2011 to 2018. The most frequent topics are Carcinoma, Squamous Cell, Cell Line, Tumor and Mouth Neoplasms. Dr. El Dinali has published most often in Oral Oncol. Dr. El Dinali's most frequent co-authors are Ezra E. Cohen, MD, Kevin Patrick White, MD and Hend Abulsayen, MD.

CMS Open Payments shows 612 general payments to Dr. El Dinali from 50 drug and device companies from 2016 to 2025. Food and beverage make up the largest share, 97% of the total. Novartis Pharmaceuticals Corporation paid the most, $1,689.